Targets › NAD1
1 program from 1 company in 1 trial: 1 Phase 2; Gastroenterology; next expected readout Dec 2027.
Open in Phaseline: the race on NAD1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Nicotinamide (NAM) NAD+ precursor; promotes NAD+ biosynthesis and may support cellular metabolism and anti-in | PARP1, NAD1, NAMPT | Phase 2 | Fatty Liver | Dec 2027 |
Fatty Liver (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.